A retrospective study of the relationship between methotrexate clearance and hyperuricemia following high-dose methotrexate therapy

Yoshihiko Shibayama, Yoshimi Yoshikawa, Kazuaki Matsumoto, Yoshihiro Shimodozono, Taeko Miyagoe, Miho Kurita, Chie Kusadome, Mariko Yamaguchi, Yaeno Nishi, Toshiro Motoya, Yasuo Takeda, Kastushi Yamada

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

Recent studies have revealed that methotrexate (MTX) is excreted by organic anion transporters (OATs), which can be inhibited by uric acid (UA). It has been reported that renal clearance of MTX was decreased in hyperuricemic rats. Here we report the relationship between MTX clearance and hyperuricema in high-dose MTX (HDMTX) chemotherapy. The authors retrospectively studied the concentration of UA in serum and the MTX clearance of 10 patients (21 cases) with HDMTX from Kagoshima University Hospital (Kagoshima, Japan). The serum UA concentration of 21 cases was significantly increased after HDMTX (pre-HDMTX: 4.11 ± 1.36 mg/dl, post-HDMTX: 5.78 ± 1.77 mg/dl, mean ± SD, p<0.0005). Abnormal values of UA (greater than 7 mg/dl) were observed in 6 cases in this study. The serum concentration of UA was transiently increased. A positive correlation between the elevation rate of serum UA and the half-life of MTX (r=0.618; p=0.002; 95%CI, 0.254 to 0.829) was observed. In conclusion, this retrospective study shows that HDMTX treatment induces hyperuricemia, suggesting that hyperuricemia may be a risk factor for delayed clearance of MTX in HDMTX chemotherapy.

Original languageEnglish
Pages (from-to)3-6
Number of pages4
JournalJournal of Applied Therapeutic Research
Volume6
Issue number1
Publication statusPublished - 2006
Externally publishedYes

Fingerprint

Hyperuricemia
Methotrexate
Uric Acid
Retrospective Studies
Serum
Therapeutics
Organic Anion Transporters
Drug Therapy
Half-Life
Japan
Kidney

Keywords

  • Hyperuricemia
  • Methotrexate
  • Therapeutic drug monitoring
  • Uric acid

ASJC Scopus subject areas

  • Pharmacology

Cite this

A retrospective study of the relationship between methotrexate clearance and hyperuricemia following high-dose methotrexate therapy. / Shibayama, Yoshihiko; Yoshikawa, Yoshimi; Matsumoto, Kazuaki; Shimodozono, Yoshihiro; Miyagoe, Taeko; Kurita, Miho; Kusadome, Chie; Yamaguchi, Mariko; Nishi, Yaeno; Motoya, Toshiro; Takeda, Yasuo; Yamada, Kastushi.

In: Journal of Applied Therapeutic Research, Vol. 6, No. 1, 2006, p. 3-6.

Research output: Contribution to journalArticle

Shibayama, Y, Yoshikawa, Y, Matsumoto, K, Shimodozono, Y, Miyagoe, T, Kurita, M, Kusadome, C, Yamaguchi, M, Nishi, Y, Motoya, T, Takeda, Y & Yamada, K 2006, 'A retrospective study of the relationship between methotrexate clearance and hyperuricemia following high-dose methotrexate therapy', Journal of Applied Therapeutic Research, vol. 6, no. 1, pp. 3-6.
Shibayama, Yoshihiko ; Yoshikawa, Yoshimi ; Matsumoto, Kazuaki ; Shimodozono, Yoshihiro ; Miyagoe, Taeko ; Kurita, Miho ; Kusadome, Chie ; Yamaguchi, Mariko ; Nishi, Yaeno ; Motoya, Toshiro ; Takeda, Yasuo ; Yamada, Kastushi. / A retrospective study of the relationship between methotrexate clearance and hyperuricemia following high-dose methotrexate therapy. In: Journal of Applied Therapeutic Research. 2006 ; Vol. 6, No. 1. pp. 3-6.
@article{be304b59a239451f9f835019b346f96f,
title = "A retrospective study of the relationship between methotrexate clearance and hyperuricemia following high-dose methotrexate therapy",
abstract = "Recent studies have revealed that methotrexate (MTX) is excreted by organic anion transporters (OATs), which can be inhibited by uric acid (UA). It has been reported that renal clearance of MTX was decreased in hyperuricemic rats. Here we report the relationship between MTX clearance and hyperuricema in high-dose MTX (HDMTX) chemotherapy. The authors retrospectively studied the concentration of UA in serum and the MTX clearance of 10 patients (21 cases) with HDMTX from Kagoshima University Hospital (Kagoshima, Japan). The serum UA concentration of 21 cases was significantly increased after HDMTX (pre-HDMTX: 4.11 ± 1.36 mg/dl, post-HDMTX: 5.78 ± 1.77 mg/dl, mean ± SD, p<0.0005). Abnormal values of UA (greater than 7 mg/dl) were observed in 6 cases in this study. The serum concentration of UA was transiently increased. A positive correlation between the elevation rate of serum UA and the half-life of MTX (r=0.618; p=0.002; 95{\%}CI, 0.254 to 0.829) was observed. In conclusion, this retrospective study shows that HDMTX treatment induces hyperuricemia, suggesting that hyperuricemia may be a risk factor for delayed clearance of MTX in HDMTX chemotherapy.",
keywords = "Hyperuricemia, Methotrexate, Therapeutic drug monitoring, Uric acid",
author = "Yoshihiko Shibayama and Yoshimi Yoshikawa and Kazuaki Matsumoto and Yoshihiro Shimodozono and Taeko Miyagoe and Miho Kurita and Chie Kusadome and Mariko Yamaguchi and Yaeno Nishi and Toshiro Motoya and Yasuo Takeda and Kastushi Yamada",
year = "2006",
language = "English",
volume = "6",
pages = "3--6",
journal = "Journal of Applied Therapeutic Research",
issn = "1029-2659",
publisher = "Euromed Communications",
number = "1",

}

TY - JOUR

T1 - A retrospective study of the relationship between methotrexate clearance and hyperuricemia following high-dose methotrexate therapy

AU - Shibayama, Yoshihiko

AU - Yoshikawa, Yoshimi

AU - Matsumoto, Kazuaki

AU - Shimodozono, Yoshihiro

AU - Miyagoe, Taeko

AU - Kurita, Miho

AU - Kusadome, Chie

AU - Yamaguchi, Mariko

AU - Nishi, Yaeno

AU - Motoya, Toshiro

AU - Takeda, Yasuo

AU - Yamada, Kastushi

PY - 2006

Y1 - 2006

N2 - Recent studies have revealed that methotrexate (MTX) is excreted by organic anion transporters (OATs), which can be inhibited by uric acid (UA). It has been reported that renal clearance of MTX was decreased in hyperuricemic rats. Here we report the relationship between MTX clearance and hyperuricema in high-dose MTX (HDMTX) chemotherapy. The authors retrospectively studied the concentration of UA in serum and the MTX clearance of 10 patients (21 cases) with HDMTX from Kagoshima University Hospital (Kagoshima, Japan). The serum UA concentration of 21 cases was significantly increased after HDMTX (pre-HDMTX: 4.11 ± 1.36 mg/dl, post-HDMTX: 5.78 ± 1.77 mg/dl, mean ± SD, p<0.0005). Abnormal values of UA (greater than 7 mg/dl) were observed in 6 cases in this study. The serum concentration of UA was transiently increased. A positive correlation between the elevation rate of serum UA and the half-life of MTX (r=0.618; p=0.002; 95%CI, 0.254 to 0.829) was observed. In conclusion, this retrospective study shows that HDMTX treatment induces hyperuricemia, suggesting that hyperuricemia may be a risk factor for delayed clearance of MTX in HDMTX chemotherapy.

AB - Recent studies have revealed that methotrexate (MTX) is excreted by organic anion transporters (OATs), which can be inhibited by uric acid (UA). It has been reported that renal clearance of MTX was decreased in hyperuricemic rats. Here we report the relationship between MTX clearance and hyperuricema in high-dose MTX (HDMTX) chemotherapy. The authors retrospectively studied the concentration of UA in serum and the MTX clearance of 10 patients (21 cases) with HDMTX from Kagoshima University Hospital (Kagoshima, Japan). The serum UA concentration of 21 cases was significantly increased after HDMTX (pre-HDMTX: 4.11 ± 1.36 mg/dl, post-HDMTX: 5.78 ± 1.77 mg/dl, mean ± SD, p<0.0005). Abnormal values of UA (greater than 7 mg/dl) were observed in 6 cases in this study. The serum concentration of UA was transiently increased. A positive correlation between the elevation rate of serum UA and the half-life of MTX (r=0.618; p=0.002; 95%CI, 0.254 to 0.829) was observed. In conclusion, this retrospective study shows that HDMTX treatment induces hyperuricemia, suggesting that hyperuricemia may be a risk factor for delayed clearance of MTX in HDMTX chemotherapy.

KW - Hyperuricemia

KW - Methotrexate

KW - Therapeutic drug monitoring

KW - Uric acid

UR - http://www.scopus.com/inward/record.url?scp=77958077231&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77958077231&partnerID=8YFLogxK

M3 - Article

AN - SCOPUS:77958077231

VL - 6

SP - 3

EP - 6

JO - Journal of Applied Therapeutic Research

JF - Journal of Applied Therapeutic Research

SN - 1029-2659

IS - 1

ER -